Bioanalytical Pharmacokinetics: The Intrinsic Value of Affimers®

Avacta presents a look at Affimers, and how they are changing R&D for the better.

By | December 13, 2017


FREE Webinar

Wednesday, January 31, 2018
9:30-11:00 AM Eastern Time
Register Now

Antibodies currently represent the gold standard of affinity reagents used for regulated bioanalysis of therapeutic proteins. Over time, traditional antibodies have been refined to the point where they are specific, sensitive, and reasonably reliable. Yet, antibodies and natural ligands have their limitations and can present challenges with supply, stability and batch-to-batch variation on assay performance. This webinar demonstrates a high-performance Affimer assay detecting and quantifying the breast cancer drug Trastuzumab, showing good sensitivity and increased dynamic range compared to the current antibody-based methods.

Topics to be covered:

  • How antibody variability impedes pharmacokinetic studies
  • What are Affimers, and when to adopt them for your R&D pipeline

Register Now

Meet the Speakers:


Amy Reeves
Assay Development Intern



Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Scientists Continue to Use Outdated Methods
  2. Secret Eugenics Conference Uncovered at University College London
  3. Like Humans, Walruses and Bats Cuddle Infants on Their Left Sides
  4. How Do Infant Immune Systems Learn to Tolerate Gut Bacteria?